BECOME A PARTICIPANT
Individuals who participate in our research studies are vital to the mission of PRISM. If you are interested in becoming a participant in one of our research studies,
learn more about the different opportunities below.
ALL STUDIES ARE CONDUCTED BY WASHINGTON STATE UNIVERSITY.
AVAILABLE STUDIES
VIRTUAL INCENTIVE TREATMENT FOR ALCOHOL (VITA)
This study is conducted by Washington State University for people who are 18 years or older and want to cut down or stop using alcohol. The behavioral intervention utilized in this study is called contingency management, in which participants receive gift cards for attending their telehealth appointments and providing blood samples consistent with a reduction in alcohol use and/or sustained abstinence from alcohol.
Alcohol use is determined by alcohol-related markers in the blood called phosphatidylethanol (PEth). Blood samples are collected by an easy at home self-collection device. The study requires participants to answer questionnaires in addition to providing blood samples at virtual visits 1-4x/month for six months with four follow-up interviews up to a year after completing the treatment phase. Participants will be randomly sorted into one of two groups during the treatment phase: Computer Based Training for Cognitive Behavior Therapy or Computer Based Training for Cognitive Behavior Therapy + Contingency Management.
Participants will be compensated at least $20 in e-gift cards for each once-a-month visit and follow-up visits and will have the chance to earn up to $1000 depending on the group they are in. If you are interested in learning more about the study, please call PRISM at (509) 818-7024 or fill out the contact information sheet below and we will contact you.
Location: Virtual
Currently recruiting; anticipated end date 2026
ZONISAMIDE FOR THE TREATMENT OF ALCOHOL USE DISORDER IN THE ADDICTION NEUROCLINICAL ASSESSMENT FRAMEWORK (ZARRA)
Washington State University and The Community Health Association of Spokane (CHAS) are partnering to conduct a study evaluate the ability of a medication called zonisamide to decrease alcohol use among treatment-seeking adults with an alcohol use disorder.
​
Participants will be asked to take a medication (either zonisamide
or matching placebo) over a period of 14 weeks at a dosing schedule that is consistent with best practices for zonisamide. They will be asked to fill out questionnaires, watch educational modules, and complete a urinalysis during the study visits. Participation will involve three visits per week from weeks 1-6, one visit per week from weeks 7-14, and three visits total at weeks 18, 27, and 54.
​
Eligibility for this study includes being between the ages 18-65, having four or more standard drinks on four or more occasions in the prior 30 days, be non-pregnant or lactating, and currently seeking alcohol use disorder treatment. Participants may receive up to approximately $463 in virtual gift cards over the course of the study.
Location: Spokane, WA
Currently recruiting; anticipated end date July 2025
PHARMACEUTICALLY-ENHANCED REINFORCEMENT FOR REDUCED ALCOHOL AND SMOKING (PERRAS)
Washington State University is partnering with Recovery Centers, Oregon Recovery and Treatment Centers and Range Community Clinic to conduct a study to evaluate the ability of evidence based behavioral treatment, called contingency management, to decrease alcohol use and cigarette smoking among treatment-seeking smokers with an alcohol use disorder who have initiated varenicline (Chantix) for smoking cessation.
​
Participants will be asked take varenicline for a 12-week treatment period. They will be asked to watch educational modules, fill out questionnaires and complete a urinalysis during the study visits. Participation will involve three visits per week from weeks 1-14 and three visits total at weeks 18, 27, and 54.
​
Eligibility for this study includes ≥ 18 years of age, having four or more standard drinks on four or more occasions in the prior 30 days, and currently seeking alcohol use disorder and smoking cessation treatment. Participants may receive up to approximately $600 in virtual gift cards over the course of the study.
Location: Spokane, WA
Currently recruiting; anticipated end date March 2025
MANAGEMENT TO REDUCE HEAVY ALCOHOL DRINKING DAYS AMONG SMOKERS RECEIVING VARENICLINE TREATMENT (CM4HDS)
Washington State University and The Community Health Association of Spokane (CHAS) are partnering to conduct a study to evaluate the ability of a well-studied behavioral intervention method, called contingency management, to decrease alcohol use and cigarette smoking among treatment-seeking smokers with an alcohol use disorder who have initiated varenicline (Chantix) for smoking cessation.
​
Participants will be asked to use a phone application that monitors smoking and alcohol use. They will be asked to submit breathalyzer samples, complete saliva samples, and fill out questionnaires at study visits. Participation will involve weekly study visits for a 9-week treatment period.
​
Eligibility for this study includes ≥ 21 years of age, currently receiving varenicline treatment 6 weeks prior to study initiation, and currently seeking alcohol use disorder treatment. Participants may receive up to approximately $670 in virtual gift cards over the course of the study.
Location: Spokane, WA
Currently recruiting; anticipated end date July 1, 2025
